New software to capture worldwide cancer data

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Researchers from Queen’s University Belfast, the Northern Ireland Cancer Registry, the International Agency for Research on Cancer and the Union for International Cancer Control have developed CanStaging+, a user-friendly tool aimed at facilitating the recording of comparable cancer staging data worldwide.

The collection of staging data at population-level is currently undertaken by population-based cancer registries. There is a large variation of data collected making it difficult to benchmark and to develop global strategies.

“Almost half of registries in Latin America and the Caribbean (52%) report staging information compared to 96% of registries in North America and Europe,” said Anna Gavin, who led the work from the Northern Ireland Cancer registry Centre for Public Health at Queen’s University Belfast.

A lack of data and inconsistency is a huge problem in high-income countries too where there were 6-37% of missing staging data for colorectal cancer across seven countries within the International Cancer Benchmarking Partnership between 2010 and 2014.

To mark the launch of the CanStaging+ tool, an accompanying article has been published in The Lancet Oncology.

Table of Contents

YOU MAY BE INTERESTED IN

When our hematological malignancy testing pilot project began in Eldoret, Kenya, there seemed to be a mismatch in relation to progress in healthcare. The region, like much of sub-Saharan Africa, had been focusing on combatting infectious diseases such as HIV and malaria—which was much-needed—yet cancer care was under-resourced. 
Artificial intelligence is rapidly transforming biomedical research and healthcare. Large language models, foundation models, and AI agents are increasingly being deployed to assist with data interpretation, literature review, clinical decision support, and translational research. 
In modern oncology, important insights from clinical trials often emerge years after initial publication. As new therapies extend survival and transition more patients into long-term remissions, clinicians and researchers are increasingly looking beyond initial response rates to understand durability, long-term safety, and even the possibility of a cure. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login